This gene test determines a patient’s risk for progression to advanced Age-related Macular Degeneration (AMD) within 2, 5 or 10 years. The test also provides a pharmacogenetic recommendation related to
AREDS supplements for AMD.
Corporate Headquarters: ArcticDx Inc.
MaRs Centre, 661 University Ave. Suite 455
Toronto, Ontario M5G 1M1 Canada
T: 1 (866) 964-5182 F: 1 (866) 964-5184
Email: firstname.lastname@example.org or email@example.com
© Arctic Group Of Companies. All Rights Reserved.